1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
AbbVie Inc.

AbbVie Inc.

4AB.DU
AbbVie Inc.DE flagDusseldorf Stock Exchange
223.60
EUR
-2.60
- -
395.05BMarket Cap
AbbVie Inc.
4AB.DU
(Dusseldorf Stock Exchange)

Recent

price

223.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.68
10.79
11.66
11.84
12.54
14.2
16.1
17.72
22.15
22.49
25.95
31.78
32.81
30.76
31.91
34.6
35.55
Revenue per Share
2.59
2.12
3.34
2.6
1.11
3.2
3.74
3.33
3.85
5.33
2.62
6.53
6.69
2.75
2.42
2.39
2.06
Basic EPS, GAAP
2.8
3.65
3.81
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
13.71
12.49
10.1
10.08
11.31
Free Cash Flow per Basic Share
- -
- -
- -
1.61
1.67
2.05
2.33
2.58
3.77
4.3
4.37
5.24
5.68
5.97
6.25
6.59
6.69
Dividend per Share
- -
7.4
2.35
1
0.35
1.41
2.76
3.44
2.29
3.2
0.61
1.78
2.71
-0.56
-4.47
-8.75
-10.1
Book Value per Share
3.6
1.81
-3.23
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.3
-52.53
-46.52
-43.89
-51.92
-51.76
-52.66
Tangible Book Value per Share
1,616
1,616
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,769
1,766
1,765
1,768
1,767
Basic Weighted Avg Shares
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
62,819
Sales/Revenue/Turnover
30.16
20.75
31.65
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
33.18
Operating Margin (%)
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
8,036
Depreciation Expense
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
3,635
Net Income, GAAP
13.61
6.41
7.86
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
39.06
Effective Tax Rate (%)
26.72
19.68
28.7
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
5.79
Profit Margin (%)
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-8,571
Working Capital
- -
32
14,630
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
64,532
LT Debt
15,703
11,932
3,363
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-6,612
Total Equity
52.42
24.76
34.74
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
19.15
14.04
- -
19.13
18.46
Return on Invested Capital (%)
- -
57.19
34.22
24.43
13.16
23.05
17.94
14.51
- -
16.59
- -
16.39
18.64
10.41
- -
10.91
9.36
Return on Capital (%)
- -
57.42
67.33
155.89
166.26
365.34
178.74
107.55
128.33
194.11
158.95
547.27
297.87
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5,772
8,555
8,326
LT Borrowings
62,971
58,941
64,532
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,767
1,768
1,767
Market Capitalization
404,148
407,700
381,774

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,539
29,062
33,529
Cash, Cash Equivalents & STI
5,671
5,257
9,391
Accounts Receivable, Net
12,769
12,589
12,479
Inventories
4,938
4,951
5,049
Total Current Liabilities
39,391
43,289
42,100
Payables & Accruals
33,619
34,734
33,774
ST Debt
5,772
8,555
8,326
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.78
0.78
0.88
-0.01
2.42
2025
0.73
0.53
0.11
1.03
2.39
2026
0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.56
1.56
1.56
6.25
2025
1.66
1.65
1.65
1.65
6.59
2026
1.75
- -
- -
- -
- -
Similar Companies
Impact Therap-b (7630.HK)
Metacare Co., Ltd. (118000.KS)
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (600613.SS)
Johnson & Johnson (JNJ)
PT Kalbe Farma Tbk (PTKFY)
Biogen Inc. (BIIB)
Business
AbbVie Inc. AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines and therapies addressing complex health issues across immunology, oncology, neuroscience, aesthetics, eye care and other therapeutic areas; key products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib) for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for hematologic oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; and additional offerings in eye care and cystic fibrosis treatments. The company, spun off from Abbott Laboratories Abbott Laboratories and founded in 2013, maintains global headquarters in North Chicago, Illinois, and conducts operations worldwide with over 50,000 employees supporting patients across multiple continents. Recent developments include the completion of its acquisition of Capstan Therapeutics in August 2025 for up to $2.1 billion to enhance targeted lipid nanoparticle technology for cell and gene therapies in autoimmune diseases and oncology; the acquisition of Gilgamesh Pharmaceuticals' lead asset bretisilocin in October 2025 for up to $1.2 billion to advance psychedelic-based treatments for depression; initiation of a $70 million expansion at its Worcester, Massachusetts biologics manufacturing facility in September 2025 to boost U.S. production capacity for oncology and immunology medicines as part of a broader $10 billion domestic investment commitment; and a $195 million expansion of its North Chicago API manufacturing site in 2025 to support neuroscience, immunology and oncology production.